Announcements Trials
Browse Landscape

Status

Terminated 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Dermatologic 6Thoracic 3Breast 3Head & Neck 2Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Breast Neoplasms 3

Interventions

Surveys and Questionnaires 79Blood Specimen Collection 67palbociclib 40Trastuzumab 34Drug Therapy 30Letrozole 29Anastrozole 27Radiotherapy 26Immunohistochemistry 26Mastectomy, Segmental 22Amplified Fragment Length Polymorphism Analysis 22Fulvestrant 21Biopsy 21exemestane 20Tamoxifen 20Interviews as Topic 20Gene Expression Profiling 20Magnetic Resonance Spectroscopy 19ribociclib 18Specimen Handling 18Mastectomy 18Neoadjuvant Therapy 17Paclitaxel 16High-Energy Shock Waves 16Capecitabine 16trastuzumab deruxtecan 15Mammography 15Psychiatric Rehabilitation 14Polymerase Chain Reaction 13Observation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Tomography, Optical Coherence × Breast × Clear all
NCT01506700 2019-07-26

Real Time Optical Coherence Tomography (OCT) of Human Tissue

Diagnostic Photonics, Inc.

Terminated
5 enrolled
Breast

Breast Neoplasms

NCT02313116 2019-07-18

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

Diagnostic Photonics, Inc.

Suspended
50 enrolled
Breast

Breast Neoplasms

NCT01699867 2015-01-06

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)

Diagnostic Photonics, Inc.

Completed
50 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡